James C M Brust1, N Sarita Shah2,3, Koleka Mlisana4,5, Pravi Moodley4,5, Salim Allana2, Angela Campbell2, Brent A Johnson6, Iqbal Master7, Thuli Mthiyane8, Simlatha Lachman9, Lee-Megan Larkan10, Yuming Ning1, Amyn Malik2, Jonathan P Smith2, Neel R Gandhi2,11. 1. Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York. 2. Rollins School of Public Health, Emory University, Atlanta, Georgia. 3. US Centers for Disease Control and Prevention, Atlanta, Georgia. 4. University of KwaZulu-Natal, Durban, South Africa. 5. National Health Laboratory Services, Durban, South Africa. 6. University of Rochester, New York. 7. King Dinuzulu Hospital, Durban. 8. South African Medical Research Council, Durban. 9. Murchison Hospital, Port Shepstone. 10. Greytown Hospital, South Africa. 11. Emory School of Medicine, Emory University, Atlanta, Georgia.
Abstract
Background: Mortality in multidrug-resistant (MDR) tuberculosis-human immunodeficiency virus (HIV) coinfection has historically been high, but most studies predated the availability of antiretroviral therapy (ART). We prospectively compared survival and treatment outcomes in MDR tuberculosis-HIV-coinfected patients on ART to those in patients with MDR tuberculosis alone. Methods: This observational study enrolled culture-confirmed MDR tuberculosis patients with and without HIV in South Africa between 2011 and 2013. Participants received standardized MDR tuberculosis and HIV regimens and were followed monthly for treatment response, adverse events, and adherence. The primary outcome was survival. Results: Among 206 participants, 150 were HIV infected, 131 (64%) were female, and the median age was 33 years (interquartile range [IQR], 26-41). Of the 191 participants with a final MDR tuberculosis outcome, 130 (73%) were cured or completed treatment, which did not differ by HIV status (P = .50). After 2 years, CD4 count increased a median of 140 cells/mm3 (P = .005), and 64% had an undetectable HIV viral load. HIV-infected and HIV-uninfected participants had high rates of survival (86% and 94%, respectively; P = .34). The strongest risk factor for mortality was having a CD4 count ≤100 cells/mm3 (adjusted hazards ratio, 15.6; 95% confidence interval, 4.4-55.6). Conclusions: Survival and treatment outcomes among MDR tuberculosis-HIV individuals receiving concurrent ART approached those of HIV-uninfected patients. The greatest risk of death was among HIV-infected individuals with CD4 counts ≤100 cells/mm3. These findings provide critical evidence to support concurrent treatment of MDR tuberculosis and HIV.
Background: Mortality in multidrug-resistant (MDR) tuberculosis-human immunodeficiency virus (HIV) coinfection has historically been high, but most studies predated the availability of antiretroviral therapy (ART). We prospectively compared survival and treatment outcomes in MDR tuberculosis-HIV-coinfectedpatients on ART to those in patients with MDR tuberculosis alone. Methods: This observational study enrolled culture-confirmed MDR tuberculosispatients with and without HIV in South Africa between 2011 and 2013. Participants received standardized MDR tuberculosis and HIV regimens and were followed monthly for treatment response, adverse events, and adherence. The primary outcome was survival. Results: Among 206 participants, 150 were HIV infected, 131 (64%) were female, and the median age was 33 years (interquartile range [IQR], 26-41). Of the 191 participants with a final MDR tuberculosis outcome, 130 (73%) were cured or completed treatment, which did not differ by HIV status (P = .50). After 2 years, CD4 count increased a median of 140 cells/mm3 (P = .005), and 64% had an undetectable HIV viral load. HIV-infected and HIV-uninfectedparticipants had high rates of survival (86% and 94%, respectively; P = .34). The strongest risk factor for mortality was having a CD4 count ≤100 cells/mm3 (adjusted hazards ratio, 15.6; 95% confidence interval, 4.4-55.6). Conclusions: Survival and treatment outcomes among MDR tuberculosis-HIV individuals receiving concurrent ART approached those of HIV-uninfectedpatients. The greatest risk of death was among HIV-infected individuals with CD4 counts ≤100 cells/mm3. These findings provide critical evidence to support concurrent treatment of MDR tuberculosis and HIV.
Authors: E A Nunes; E M De Capitani; E Coelho; O A Joaquim; I R O Figueiredo; A M Cossa; A C Panunto; M Carvalho-Ramos Journal: Int J Tuberc Lung Dis Date: 2005-05 Impact factor: 2.373
Authors: Elize Pietersen; Elisa Ignatius; Elizabeth M Streicher; Barbara Mastrapa; Xavier Padanilam; Anil Pooran; Motasim Badri; Maia Lesosky; Paul van Helden; Frederick A Sirgel; Robin Warren; Keertan Dheda Journal: Lancet Date: 2014-01-17 Impact factor: 79.321
Authors: James C M Brust; N Sarita Shah; Theo L van der Merwe; Sheila Bamber; Yuming Ning; Moonseong Heo; Anthony P Moll; Marian Loveday; Umesh G Lalloo; Gerald H Friedland; Neel R Gandhi Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Neel R Gandhi; N Sarita Shah; Jason R Andrews; Venanzio Vella; Anthony P Moll; Michelle Scott; Darren Weissman; Claudio Marra; Umesh G Lalloo; Gerald H Friedland Journal: Am J Respir Crit Care Med Date: 2009-10-15 Impact factor: 21.405
Authors: Jason E Farley; Malathi Ram; William Pan; Stacie Waldman; Gail H Cassell; Richard E Chaisson; Karin Weyer; Joey Lancaster; Martie Van der Walt Journal: PLoS One Date: 2011-07-22 Impact factor: 3.240
Authors: Max R O'Donnell; Nesri Padayatchi; Charlotte Kvasnovsky; Lise Werner; Iqbal Master; C Robert Horsburgh Journal: Emerg Infect Dis Date: 2013-03 Impact factor: 6.883
Authors: Johnny Flippie Daniels; Mohammed Khogali; Erika Mohr; Vivian Cox; Sizulu Moyo; Mary Edginton; Sven Gudmund Hinderaker; Graeme Meintjes; Jennifer Hughes; Virginia De Azevedo; Gilles van Cutsem; Helen Suzanne Cox Journal: PLoS One Date: 2015-11-10 Impact factor: 3.240
Authors: Jeffrey M Collins; Amnah Siddiqa; Dean P Jones; Ken Liu; Russell R Kempker; Azhar Nizam; N Sarita Shah; Nazir Ismail; Samuel G Ouma; Nestani Tukvadze; Shuzhao Li; Cheryl L Day; Jyothi Rengarajan; James Cm Brust; Neel R Gandhi; Joel D Ernst; Henry M Blumberg; Thomas R Ziegler Journal: JCI Insight Date: 2020-05-21
Authors: D M Kokebu; S Ahmed; R Moodliar; C-Y Chiang; G Torrea; A Van Deun; R L Goodall; I D Rusen; S K Meredith; A J Nunn Journal: Int J Tuberc Lung Dis Date: 2022-08-01 Impact factor: 3.427
Authors: Gregory P Bisson; Mayara Bastos; Jonathon R Campbell; Didi Bang; James C Brust; Petros Isaakidis; Christoph Lange; Dick Menzies; Giovanni B Migliori; Jean W Pape; Domingo Palmero; Parvaneh Baghaei; Payam Tabarsi; Piret Viiklepp; Stalz Vilbrun; Jonathan Walsh; Suzanne M Marks Journal: Lancet Date: 2020-08-08 Impact factor: 79.321
Authors: Gilbert Lazarus; Kevin Tjoa; Anthony William Brian Iskandar; Melva Louisa; Evans L Sagwa; Nesri Padayatchi; Vivian Soetikno Journal: PLoS One Date: 2021-03-04 Impact factor: 3.240
Authors: Jonathan P Smith; Neel R Gandhi; N Sarita Shah; Koleka Mlisana; Pravi Moodley; Brent A Johnson; Salim Allana; Angela Campbell; Kristin N Nelson; Iqbal Master; James C M Brust Journal: J Acquir Immune Defic Syndr Date: 2020-01-01 Impact factor: 3.771
Authors: Joseph Baruch Baluku; Pallen Mugabe; Rose Mulwana; Sylvia Nassozi; Richard Katuramu; William Worodria Journal: Biomed Res Int Date: 2020-07-25 Impact factor: 3.411
Authors: Tyler S Brown; Lavanya Challagundla; Evan H Baugh; Shaheed Vally Omar; Arkady Mustaev; Sara C Auld; N Sarita Shah; Barry N Kreiswirth; James C M Brust; Kristin N Nelson; Apurva Narechania; Natalia Kurepina; Koleka Mlisana; Richard Bonneau; Vegard Eldholm; Nazir Ismail; Sergios-Orestis Kolokotronis; D Ashley Robinson; Neel R Gandhi; Barun Mathema Journal: Proc Natl Acad Sci U S A Date: 2019-10-28 Impact factor: 11.205